Peptide Research Hub
Educational reference
Educational reference only. Nothing on this site is medical advice. Many compounds described here are not FDA-approved, lack adequate human evidence, and may be illegal in your jurisdiction. Always consult a licensed clinician.

Nootropic & Neuropeptides

Selank

Also known as: TP-7 Tuftsin analog

Evidence: Limited human data Disclaimer: Elevated Approved in Russia; not FDA-approved
Elevated-disclaimer compound. Not approved by the FDA. Evidence is limited to animal models or small human studies. Safety in humans has not been established.

Mechanism & research context

Synthetic tuftsin analog approved in Russia for generalized anxiety. Limited Western-standard clinical evidence.

Safety flags

0 flags

No curator-recorded safety flags for this entry. Absence of recorded flags is not evidence of safety. Many peptides lack adequate human data.

Research papers

16 records

Citation links route to PubMed, Europe PMC, and PMC. Presence of a study is not endorsement. Records are refreshed from PubMed on a regular cadence; rows marked “Live search link” will resolve to a current PubMed search until a full citation has been ingested.

Clinical trials

11 records
  • Live search Live search

    Live ClinicalTrials.gov search: Selank

    Condition: See live results

    Open on ClinicalTrials.gov ↗
  • NCT00464269 PHASE3 COMPLETED

    An International, Double-blind, Parallel-group, Placebo-controlled, Randomized Study: Evaluation of the Efficacy and Safety of Brivaracetam in Subjects (>= 16 to 70 Years Old) With Partial Onset Seizures

    Condition: Epilepsy

    Sponsor: UCB Pharma

    Open on ClinicalTrials.gov ↗
  • NCT00504881 PHASE3 COMPLETED

    An International, Randomized, Double-blind, Parallel-group, Placebo-controlled, Flexible Dose Study: Evaluation of the Safety and Efficacy of Brivaracetam in Subjects (≥ 16 to 70 Years Old) Suffering From Localization-related or Generalized Epilepsy.

    Condition: Epilepsy

    Sponsor: UCB Pharma SA

    Open on ClinicalTrials.gov ↗
  • NCT01747200 NA COMPLETED

    Modulating Behavior in Humans by Entrainment With Rhythmic Transcranial Magnetic Stimulation

    Condition: Repetitive TMS (rTMS); Sham rTMS; Bilateral rTMS; Unilateral rTMS

    Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)

    Open on ClinicalTrials.gov ↗
  • NCT01770990 NA COMPLETED

    Randomized Trial of Telephone-Based Psychotherapy for Depression With and Without Adjunctive Supportive Mail

    Condition: Depression

    Sponsor: Universitätsklinikum Hamburg-Eppendorf

    Open on ClinicalTrials.gov ↗
  • NCT04989088 NA UNKNOWN

    Neurofeedback Training to Restore Hemispheric Imbalance in Dyslexia

    Condition: Dyslexia; Reading Problem

    Sponsor: Catholic University of the Sacred Heart

    Open on ClinicalTrials.gov ↗
  • NCT05076045 NA COMPLETED

    Immediate Effects of Personal Sound Amplification Products on Speech Processing

    Condition: Hearing Loss, Age-Related

    Sponsor: Rotman Research Institute at Baycrest

    Open on ClinicalTrials.gov ↗
  • NCT05411185 COMPLETED

    The Study on Effects of Acute Exposure to High Altitude Hypoxia on Cognitive Function in Lowlanders

    Condition: Cognition

    Sponsor: Xijing Hospital

    Open on ClinicalTrials.gov ↗
  • NCT05832060 NA UNKNOWN

    Comparing the Efficacy of tDCS and tRNS to Improve Reading Skills in Children and Adolescents With Dyslexia

    Condition: Developmental Dyslexia

    Sponsor: Bambino Gesù Hospital and Research Institute

    Open on ClinicalTrials.gov ↗
  • NCT06151093 NA COMPLETED

    Investigating the Effects of Video-Based Balance Games and Balance Exercises on Visual-Spatial Attention With EEG Brain Oscillations

    Condition: EEG Brain Oscillations; Balance Exercises

    Sponsor: Istanbul Medipol University Hospital

    Open on ClinicalTrials.gov ↗
  • NCT07196085 NA COMPLETED

    Neural Mechanisms and Efficacy of Imagery Rescripting for Fear of Failure: A Randomized Controlled Neuroimaging Trial

    Condition: Fear of Failure

    Sponsor: University of Social Sciences and Humanities, Warsaw

    Open on ClinicalTrials.gov ↗

Doses reported in studies

0 records
This is not a dosing guide. Entries below are historical metadata transcribed verbatim from a cited clinical-trial protocol, published study, or FDA-approved label. They describe what was administered in a specific study population under medical supervision — they are not recommendations, not common-use guidance, and may not be safe or appropriate outside the cited context. Doses widely discussed in community/anecdotal sources are not shown here; see the safety policy for why.

No study-protocol dose records have been curated for Selank yet. Absence of records is not evidence of safety — many peptides lack adequate human-trial data in the first place.

Records here are populated from public sources only (ClinicalTrials.gov protocol summaries and FDA-approved labels) and must cite a verifiable source URL. They are not added from forum posts, vendor pages, anecdotal write-ups, or social media.

These entries describe what was studied. They do not tell you what to take, how to reconstitute anything, how to fill a capsule, how often to administer, or where to obtain a compound. If you are considering use of Selank, those decisions belong with a licensed clinician working from the full label or trial record — not from this summary.

Why this page does not list a dose for self-use

The "Doses reported in studies" section above (when populated) describes what was administered in a cited study or label, under medical supervision, in a specific population. It is not a dosing guide for self-use. Separately, we do not publish anecdotal or community-reported dose ranges, administration methods, vial concentrations, or capsule masses for Selank. Anecdotal figures for unapproved compounds are not harm-reduction data: they lack denominators for adverse events, cannot account for individual physiology or compound purity, and normalise unsupervised use. See the safety policy for the full reasoning.

If this compound has an FDA-approved label

If a label exists, the regulator-reviewed dosing and administration information is there — read it in the context of a prescriber's evaluation.

Questions worth bringing to a clinician

  • What is the evidence for this compound in someone with my history?
  • What are the realistic, regulator-reviewed alternatives?
  • What would you monitor, and what would make you stop?

If you have already taken a peptide and feel unwell: contact emergency services. In the United States, Poison Control is reachable 24/7 at 1-800-222-1222. Do not wait for a community thread.

Research peptides are not substitutes for medical care. If you are considering any peptide for health purposes, speak with a board-certified physician or endocrinologist first.